The Latest Breaking News from Quest Diagnostics

Despite Quest Diagnostics' outperformance relative to its industry peers over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Despite Quest Diagnostics’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

With Quest Diagnostics gearing up to release its third-quarter earnings later this month, analysts expect a low single-digit earnings growth.

As Quest Diagnostics underperformed relative to the S&P 500 Index over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

As Quest Diagnostics gears up to unveil its second-quarter earnings results, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Plus, an AI-generated version of the same article

Fitbit and Pixel Watch owners can participate in a metabolic health study, which involves providing digital health data and a blood sample.

Amphetamine use is on the rise as well.

ST. LOUIS — While marijuana legalization proponents celebrated victory in their fight for recreational cannabis, Missouri business owners were phoning their lawyers.

Masimo Corporation (NASDAQ: MASI) delivered adjusted earnings per share (ETF:EPS) of $1.35 in the second quarter of 2022, up 43.6% year over year. The figure surpassed the Zacks Consensus Estimate by 13.5%.

The Biden administration has started shipping testing kits for monkeypox to commercial laboratories, in a bid to speed diagnostic tests for suspected infections for the virus that has already infected at least 142 people in the U.S. The Centers for Disease Control and Prevention is sending tests to commercial labs,…